HT-X Science
Cardio-regeneration Innovation Center, CRIC
Cardiology
Heart failure (HF) is a life-threatening syndrome with substantial morbidity and mortality, affecting an estimated 38 million patients worldwide. It has become a major burden in developed countries because of its substantial readmission rate, poor prognosis, and increasing prevalence with population aging, the rising prevalence of lifestyle risk factors, improved outcomes of acute cardiac conditions, and improvements in HF management. HF is now becoming more common in China, where aging and high-income-country lifestyle changes lead to more risk factors for the development of HF. Transplantation of pluripotent stem cell-derived cardiomyocytes represents a regenerative therapeutic concept with great potential for the treatment of patients with heart failure. It was successfully applied in various preclinical studies and is currently evaluated in the first clinical trials (i.e., HEAL-CHF [Treating Heart Failure With hPSC-CMs], NCTO3763136).
Cited from Stüdemann Tim et al. Circulation 2022 and Hua Wang et al. Circulation 2021
Cited from Stüdemann Tim et al. Circulation 2022 and Hua Wang et al. Circulation 2021
Process
Two-Track regulatory system for clinical stage
The clinical study of HiCM-188 was filed by National Health Commission of China collaborated with Prof. Dongjin WANG (Nanjing Drum Tower Hospital) in 2021(Certification No.MR-32-21- 014649).
IND was submitted both in China and US in 2022.
IND was submitted both in China and US in 2022.
iPSC-drived cardiomyocyte products were issued by China National Institutes for Food and Drug Control (SH202005071).
Advisor
International Advisor
Prof. Philippe Menasché, Chief Scientific Advisor
Professor of the UAB Department of Biomedical Engineering, clinical cardiac surgeon at the Hôpital Européen Georges Pompidou, Professor of Thoracic and Cardiovascular Surgery at the University of Paris Descartes
Prof. Emerson Perin
Provided leadership at the Texas Heart Institute for over 25 years, world-renowned cardiologist known for his leadership in the development of stem cell therapies for cardiovascular diseases, Director of the Center for Clinical Research, Director of the Stem Cell Center and the Medical Director of THI, at the Texas Heart Institute
Prof. Daniel Burkhoff
Director of Heart Failure, Hemodynamics and MCS Research at Cardiovascular Research Foundation. Dr Burkhoff's interest include cardiovascular modeling and ventricular mechanics, cardiovascular monitoring, heart failure, device and pharmacologic treatments for heart failure
Domestic Advisor
Prof. Junbo GE
Academician of the Chinese Academy of Sciences, Dean of the Shanghai Institute of Cardiovascular Diseases, Dean of the First Hospital affiliated to the University of Science and Technology of China
Prof. Zhongmin LIU
Honorary Dean of the Shanghai East Hospital, Academician of the Russian Academy of Engineering
Prof. Dongjin WANG
Professor of cardiovascular surgery, the Director of the Department of Cardiothoracic Surgery at the Nanjing Drum Tower Hospital, awarded the Best Cardiac Surgeon in China (Gold Knife Award) in 2008
Prof. Jay WANG
Professor at the Jiangsu Province hospital & Jiangsu Clinical Research Institution
Joint lab of ophthalmic diseases, OD Lab
Ophthalmology
AMD is one of the major causes of vision loss among people aged 50 years and older. It is a polygenic disease with aging and cigarette smoking as key risk factors that trigger risk alleles to manifest with age. The advanced stage of AMD, geographic atrophy (GA), leads to vision loss and often blindness, is characterized by irreversible degeneration of the photoreceptors and retinal pigment epithelium (RPE).
In recent years, a paper on Cell Stem Cell confirmed that RPE cells differentiated from induced pluripotent stem cells (iPSC) were not rejected by the immune system. RPE holds great promise for the treatment of AMD.
Cited from Ruchi Sharma et al. Nat Commun. 2021
In recent years, a paper on Cell Stem Cell confirmed that RPE cells differentiated from induced pluripotent stem cells (iPSC) were not rejected by the immune system. RPE holds great promise for the treatment of AMD.
Cited from Ruchi Sharma et al. Nat Commun. 2021
Process
Help Thera-X, a leading global iPSC-derived cell therapy provider, announced a partnership with University of Macau to set up a new lab in Zhuhai City for regenerative medicine research. This five-year partnership is devoted to exploring cutting-edge application of iPsC-derived cell products.
The translational research and research on preclinical efficacy based on "iPSC-derived RPE for the treatment of AMD" collaborated with Jiangsu Province Hospital were honored as 2022 Jiangsu Provincial S&T Program and Nanjing Life Science Project.
The translational research and research on preclinical efficacy based on "iPSC-derived RPE for the treatment of AMD" collaborated with Jiangsu Province Hospital were honored as 2022 Jiangsu Provincial S&T Program and Nanjing Life Science Project.
Partner
iPSC-driven Neuroscience Lab, iN Lab
Neuroscience
Parkinson's disease is the second largest neurodegenerative diseases. Its cardinal features include motor symptoms such as bradykinesia, rigidity, resting tremor and postural instability, though nonmotor symptoms are often also present. Current pharmacologic therapy involves dopamine supplements, dopamine agonists, and antagonists inhibiting dopamine degradation. These treatments gradually lose their effectiveness with long-time use, where cell therapy, on the other hand, holds the promise. Cell transplantation with fetal tissue has been proved to be effective for treating PD during the last four decades. Despite of fetal tissue, iPsC-derived dopamine cells take advantage of reliable cell resource and no ethical concerns, and have been applied from bench to bedside.
Cited from Jinghua Piao et al. Cell Stem Cell. 2021
Cited from Jinghua Piao et al. Cell Stem Cell. 2021
Process
Help Thera-X, based on its patent — recombinant lentivirus-induced differentiation of neural stem cells into dopaminergic neurons (CN201310229277.7),cooperated with research institutes such as Nantong University to continuously explore clinical application of neural stem cell in treating PD.
Motor Rehabilitation Lab, MR Lab
Motor System
Mesenchymal stem cell (MSC) is an ideal cell source for tissue regeneration. MSCs exist in almost all tissues, such as bone marrow, adipose tissue, and synovium, and are easily extracted. MSCs are multipotent, which means they have the ability to differentiate into many kinds of cell types within a lineage. MSCs exert an effect on a range of cells involved in the immune response and have been used as an immuse tolerant agent because of the effects like anti-inflammatory, immunoregulatory, and immunosuppressive capacities. Proven to be safe and effective, MSC therapy has been qranted reaulatory approval in several countries.
Cited from Yu Hanet al. Cell. 2019
Cited from Yu Hanet al. Cell. 2019
Process
Help Thera-X holds the cutting-edge technology in manufacturing cell products. With our automatic Cell Foundry platform, we continuously produce cells with high quality and low cost to meet the needs on the market.
